Jardiance Medicare Part D Coverage: Formulary Status, Copays, and Savings Programs in 2026

How Medicare Part D Covers Jardiance

Medicare Part D plans are required to cover at least two drugs in each pharmacological class, and SGLT2 inhibitors like empagliflozin appear on the majority of formularies. Jardiance typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), depending on the plan's negotiated rebate agreements with Boehringer Ingelheim [1].

Formulary placement matters because it dictates cost-sharing. A Tier 3 placement usually means a fixed copay of $35 to $50 per 30-day supply during the initial coverage phase, while Tier 4 placement can push copays to $80 to $100 or require coinsurance of 25% to 40% [2]. The Centers for Medicare & Medicaid Services (CMS) publishes the Medicare Plan Finder tool, which lets beneficiaries search specific plan formularies by ZIP code and drug name [3].

Each Part D plan can set its own utilization management rules. Some plans require prior authorization for empagliflozin, particularly when prescribed for heart failure rather than diabetes [4]. Step therapy requirements may also apply, requiring a trial of metformin or a sulfonylurea before covering an SGLT2 inhibitor for glycemic control [5]. Beneficiaries who face a coverage denial can file an exception request with supporting documentation from their prescriber, and plans must respond within 72 hours for standard requests or 24 hours for expedited requests [3].

The American Diabetes Association's 2024 Standards of Care recommend SGLT2 inhibitors as first-line therapy alongside metformin for patients with type 2 diabetes who have established cardiovascular disease or are at high cardiovascular risk [6]. This guideline-level endorsement strengthens exception requests when plans restrict access.

The Inflation Reduction Act and the $2,000 Out-of-Pocket Cap

The most significant change to Part D in decades took effect on January 1, 2025. The Inflation Reduction Act (IRA) restructured the Part D benefit to cap total out-of-pocket spending at $2,000 per year, eliminating the previous coverage gap (the "donut hole") where beneficiaries paid 25% coinsurance on all prescriptions [7].

Before the IRA, a Medicare beneficiary taking Jardiance could face catastrophic-phase spending that exceeded $3,000 annually. Under the new structure, once a beneficiary reaches $2 to 000 in true out-of-pocket costs, they pay nothing for the remainder of the calendar year [8]. CMS estimates that approximately 1.5 million Medicare beneficiaries taking brand-name diabetes medications will save an average of $400 per year under this cap [7].

The IRA also introduced the Medicare Prescription Payment Plan, which allows beneficiaries to spread their annual out-of-pocket costs across monthly installments rather than paying large copays at the pharmacy counter [9]. This is not a discount program. It is an interest-free payment plan that smooths cash flow. Enrollment is voluntary and can be initiated through the Part D plan, at the pharmacy, or via 1-800-MEDICARE [9].

A separate IRA provision capped insulin copays at $35 per month for all Part D enrollees, effective January 2023 [10]. While this provision applies specifically to insulin products, it signals the legislative direction toward branded diabetes drug affordability within Medicare.

What Jardiance Actually Costs Under Part D

Real-world out-of-pocket costs vary based on three factors: plan formulary tier, annual deductible, and whether the beneficiary qualifies for Extra Help. The standard Part D deductible for 2026 is $590 [11]. Beneficiaries must pay full price for non-exempt drugs until they meet this deductible, which means the first month's fill of Jardiance could cost several hundred dollars out of pocket.

After the deductible, cost-sharing during the initial coverage phase depends on tier. For a Tier 3 drug, a representative plan might charge a $47 copay. For a Tier 4 drug, the same plan might charge 33% coinsurance on the negotiated price, translating to roughly $95 per fill [2]. These costs accumulate toward the $2,000 annual cap.

A beneficiary taking only Jardiance (10 mg or 25 mg daily) at a plan-negotiated price of $550 per month would reach the $2,000 cap by approximately month four or five, after which all subsequent fills would cost $0 for the rest of the year. Beneficiaries on multiple brand-name medications will reach the cap sooner.

Dr. Judit Meszaros, PharmD, a Medicare formulary analyst, has noted: "The $2,000 cap fundamentally changes the math for beneficiaries on SGLT2 inhibitors. Patients who previously rationed doses to avoid donut-hole costs should no longer need to."

Extra Help (Low-Income Subsidy) and Jardiance

Medicare's Extra Help program, also called the Low-Income Subsidy (LIS), covers premiums, deductibles, and copays for beneficiaries with limited income and resources. In 2026, full-subsidy beneficiaries pay $0 for generic drugs and $4.50 for brand-name drugs per fill, while partial-subsidy beneficiaries pay a 15% coinsurance rate [12].

Eligibility thresholds for 2026 are approximately $23,340 annually for individuals and $31,500 for married couples, with asset limits of $17,220 and $34,360 respectively [12]. The IRA expanded deemed eligibility so that beneficiaries at or below 150% of the federal poverty level automatically qualify for full Extra Help benefits, a change from the previous 135% threshold [7].

For a Jardiance user who qualifies for full Extra Help, the annual out-of-pocket cost drops from potentially $2,000 to roughly $54 (12 fills at $4.50 each) [12]. Applications can be submitted through the Social Security Administration at ssa.gov or by calling 1-800-772-1213. State Health Insurance Assistance Programs (SHIPs) provide free one-on-one counseling to help beneficiaries manage the application [3].

Manufacturer Programs and Commercial Coupons

Boehringer Ingelheim offers a Jardiance Savings Card for commercially insured patients that can reduce copays to as little as $10 per month [13]. This program is not available to Medicare, Medicaid, or other federal healthcare program beneficiaries. The prohibition comes from the federal Anti-Kickback Statute, which bars pharmaceutical manufacturers from offering financial incentives that could influence prescribing decisions for federally funded programs [14].

The Boehringer Ingelheim Cares Foundation operates a patient assistance program (PAP) that provides free Jardiance to uninsured or underinsured patients who meet income requirements, generally at or below 400% of the federal poverty level [13]. Medicare beneficiaries who have not yet met their deductible and face high initial costs may qualify for this program during the gap period, though eligibility is evaluated case by case.

State Pharmaceutical Assistance Programs (SPAPs) in 23 states provide supplemental coverage that can reduce Part D cost-sharing [15]. These programs vary by state. New York's EPIC program, for example, covers Part D copays for residents aged 65+ with incomes up to $75,000 for singles and $100,000 for couples [15].

Why Jardiance Is Priced as a Brand-Name Drug

Empagliflozin holds active patents and regulatory exclusivities that prevent generic entry through at least 2027 [16]. The FDA's Orange Book lists multiple patents covering the compound, formulation, and methods of use for cardiovascular and renal indications [17]. Boehringer Ingelheim has pursued additional pediatric exclusivity extensions, adding six months beyond existing patent terms [16].

The pricing reflects the drug's clinical evidence base. EMPA-REG OUTCOME (N=7,020) demonstrated that empagliflozin reduced cardiovascular death by 38% relative to placebo in patients with type 2 diabetes and established cardiovascular disease (HR 0.62 to 95% CI 0.49-0.77, P<0.001) [18]. EMPEROR-Reduced (N=3,730) showed a 25% reduction in the combined risk of cardiovascular death or hospitalization for heart failure in patients with HFrEF (HR 0.75 to 95% CI 0.65-0.86, P<0.001) [19]. EMPEROR-Preserved (N=5,988) extended the heart failure indication to HFpEF, showing a 21% reduction in the composite endpoint (HR 0.79 to 95% CI 0.69-0.90, P<0.001) [20].

EMPA-KIDNEY (N=6,609) demonstrated a 28% reduction in kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64-0.82, P<0.001), leading to the FDA's 2023 approval of empagliflozin for chronic kidney disease regardless of diabetes status [21]. Each new indication expands the eligible patient population while maintaining brand pricing. The 2024 AHA/ACC/HFSA heart failure guidelines give SGLT2 inhibitors a Class I recommendation for all stages of heart failure [22].

Comparing Cost Strategies: Switching vs. Appealing

When a Part D plan places Jardiance on a higher tier, beneficiaries face a choice between requesting a formulary exception and switching to a lower-tier SGLT2 inhibitor. Dapagliflozin (Farxiga) and canagliflozin (Invokana) are the two alternatives within the class, and plan formularies may favor one over another based on rebate negotiations [2].

The clinical evidence does not strongly favor one SGLT2 inhibitor over another for most indications. A 2022 network meta-analysis published in The Lancet Diabetes & Endocrinology comparing SGLT2 inhibitors across cardiovascular, renal, and mortality outcomes found no statistically significant differences between empagliflozin and dapagliflozin for major adverse cardiovascular events [23]. Switching within the class is generally considered clinically appropriate when cost is the primary barrier, though the 2024 KDIGO guidelines note that empagliflozin and dapagliflozin have the strongest renal evidence base [24].

For beneficiaries who prefer to stay on Jardiance, the formulary exception process requires the prescriber to submit a letter documenting medical necessity. CMS regulations require plans to grant exceptions when the requested drug is medically necessary because alternatives have been tried and failed, are contraindicated, or would cause adverse effects [3]. Plans that deny exceptions must provide written notice with appeal rights. The first level of appeal is an independent review entity (IRE) determination, and approximately 40% of Part D IRE appeals result in overturn of the plan's decision [25].

Choosing the Right Part D Plan During Open Enrollment

The annual Medicare Open Enrollment Period runs from October 15 to December 7. Beneficiaries taking Jardiance should compare plans annually because formulary tiers, copay structures, and preferred pharmacy networks change each year [3].

The Medicare Plan Finder at medicare.gov allows users to enter their specific medications, doses, pharmacy preference, and ZIP code to generate personalized cost estimates [3]. Key variables to compare include monthly premium, annual deductible, Jardiance tier placement, cost-sharing percentage in each coverage phase, and whether the preferred pharmacy offers additional discounts [11].

Medicare Advantage Prescription Drug (MAPD) plans bundle Part D with Parts A and B, and they may offer lower drug copays than standalone Part D plans in exchange for network restrictions on medical providers [2]. For beneficiaries whose primary cost driver is a brand-name medication like Jardiance, an MAPD plan with Tier 3 placement and a low deductible may offer the best overall value.

SHIP counselors are available in every state to help with plan comparisons at no cost. The program is funded by CMS and can be reached through the Eldercare Locator at 1-800-677-1116 [3].

Jardiance for Heart Failure: Coverage Nuances

The FDA approved empagliflozin for heart failure with reduced ejection fraction in 2021 and for heart failure with preserved ejection fraction in 2022 [17]. The 2023 CKD indication further expanded the approved uses [21]. These broader approvals affect Part D coverage because plans may apply different utilization management criteria depending on the diagnosis code submitted with the claim.

When empagliflozin is prescribed for heart failure in a patient without diabetes, prior authorization is more common [4]. The prescriber must document the diagnosis (ICD-10 codes I50.2x for systolic HF, I50.3x for diastolic HF) and may need to attest that the patient meets trial enrollment criteria. EMPEROR-Reduced enrolled patients with LVEF ≤40% and NYHA class II-IV symptoms regardless of diabetes status [19]. EMPEROR-Preserved enrolled patients with LVEF >40% [20].

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of type 2 diabetes supports SGLT2 inhibitor use across cardiorenal indications and notes that prior authorization requirements should not delay initiation in high-risk patients [26]. If a plan denies coverage for a heart failure indication, the exception request should cite the FDA-approved labeling and the Class I recommendation from the 2024 AHA/ACC/HFSA guideline [22].

Looking Ahead: Generic Empagliflozin and Biosimilar Pricing

The earliest projected date for generic empagliflozin entry is 2027, based on current patent expiry schedules listed in the FDA Orange Book [16]. Patent challenges under the Hatch-Waxman Act paragraph IV certification process could accelerate or delay this timeline. As of early 2026, no ANDA (Abbreviated New Drug Application) for generic empagliflozin has received tentative approval from the FDA [17].

When generics do enter the market, historical patterns suggest an initial price reduction of 15% to 30% within the first year, accelerating to 70% to 90% below brand price once three or more generic manufacturers are active [27]. For context, generic atorvastatin (Lipitor) saw a 95% price reduction within five years of generic entry.

Until then, the $2,000 annual Part D cap, Extra Help, SPAPs, and careful plan selection remain the primary cost-mitigation tools for Medicare beneficiaries prescribed Jardiance. Beneficiaries who fill prescriptions at preferred pharmacies in their plan's network can save an additional 10% to 20% on copays compared to non-preferred pharmacies [11].